US 7,320,970 B2
Low dose estrogen interrupted hormone replacement therapy
Robert F. Casper, Toronto (Canada); Gary A. Shangold, Califon, N.J. (US); and Militza K. Ausmanas, Lake Forest, Ill. (US)
Assigned to Duramed Pharmaceutials, Inc., Cincinnati, Ohio (US); and Jencap Research Ltd., Toronto, Ontario (Canada)
Filed on May 24, 2006, as Appl. No. 11/439,171.
Application 11/439171 is a continuation of application No. 10/806613, filed on Mar. 22, 2004, granted, now 7,078,394, filed on Jul. 18, 2006.
Application 10/806613 is a continuation of application No. 10/134455, filed on Apr. 30, 2002, granted, now 6,747,019, filed on Jun. 08, 2004.
Application 10/134455 is a continuation of application No. 09/538485, filed on Mar. 30, 2000, abandoned.
Claims priority of provisional application 60/126970, filed on Mar. 30, 1999.
Prior Publication US 2006/0211663 A1, Sep. 21, 2006
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/56 (2006.01)
U.S. Cl. 514—170 10 Claims
 
1. A method of treating a female in need of hormone replacement therapy, the method comprising administering:
(a) three consecutive daily dosage forms or an equivalent thereof comprising a substance exhibiting estrogenic activity; followed by
(b) three consecutive daily dosage forms or an equivalent thereof comprising a substance exhibiting estrogenic activity and a substance exhibiting progestogenic activity equivalent to about 90 μg norgestimate per day.